A fresh report has been added to the wide database of Market Research Hub (MRH). The research study is titled “Dermatomyositis - Pipeline Review, H2 2017”which encloses important data about the production, consumption, revenue and market share, merged with information related to the market scope and product overview. The report anticipates that the sector for pharmaceutical industry would rise at a positive CAGR during the period 2017-2022.
Click here for Free Sample Report@ https://www.marketresearchhub.com/enquiry.php?type=S&repid=1381804
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dermatomyositis - Pipeline Review, H2 2017, provides an overview of the Dermatomyositis (Musculoskeletal Disorders) pipeline landscape.
Dermatomyositis is a rare inflammatory disease which is characterized by chronic muscle inflammation accompanied by muscle weakness. Symptoms of dermatomyositis include a distinctive skin rash, muscle weakness, and inflammatory myopathy, or inflamed muscles. Risk factors include age and gender. Treatment includes corticosteroids.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dermatomyositis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Dermatomyositis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Dermatomyositis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dermatomyositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 6, 4 and 1 respectively.
Dermatomyositis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Dermatomyositis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Dermatomyositis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dermatomyositis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dermatomyositis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dermatomyositis (Musculoskeletal Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dermatomyositis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dermatomyositis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Browse Full Report with TOC@ https://www.marketresearchhub.com/report/dermatomyositis-pipeline-review-h2-2017-report.html
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Global Markets Direct Report Coverage 6
Dermatomyositis - Overview 7
Dermatomyositis - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Products under Development by Companies 10
Dermatomyositis - Therapeutics Assessment 11
Assessment by Target 11
Assessment by Mechanism of Action 13
Assessment by Route of Administration 15
Assessment by Molecule Type 17
Dermatomyositis - Companies Involved in Therapeutics Development 19
Bristol-Myers Squibb Co 19
Chugai Pharmaceutical Co Ltd 19
Eli Lilly and Co 20
Hope Pharmaceuticals Inc 20
Idera Pharmaceuticals Inc 21
KPI Therapeutics Inc 21
MedImmune LLC 21
Neovacs SA 22
Novartis AG 22
Octapharma AG 23
Pfizer Inc 23
Dermatomyositis - Drug Profiles 25
abatacept - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
baricitinib - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
dalazatide - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
immune globulin (human) - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
IMO-8400 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
lenabasum - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
MEDI-7734 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
PF-06823859 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
siponimod - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
sodium thiosulfate - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
tocilizumab - Drug Profile 76
Product Description 76
Enquire about this Report@ https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1381804